TIANJIN DEV (00882) announced that on December 24, 2025, its indirectly non-wholly owned subsidiary, Lisheng Pharmaceutical, entered into the 12th wealth management agreement with Industrial Bank Co., Ltd. to subscribe for a structured deposit with a principal amount of RMB85 million (approximately HKD93.41 million).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments